Nuvectis Pharma Inc (NVCT NASDAQ) stock market data APIs
$6.3477
-0.14(-2.2%)
as of September 18, 2025
Try our APIs with
free plan!
Nuvectis Pharma Inc Financial Data Overview
Price chart is built with
Anychart
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Prev. Close
6.3477
Open
6.2041
High
6.5715
Low
6.2041
52 wk Range
4.44-11.8
Market Cap
158 M
Shares Outstanding
25 457 K
EPS
-0.3
Beta
-0.278
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nuvectis Pharma Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nuvectis Pharma Inc data using free add-ons & libraries
Get Nuvectis Pharma Inc Fundamental Data
Nuvectis Pharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-05
- EPS/Forecast: -0.25
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nuvectis Pharma Inc News
New
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
Fort Lee, NJ, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovati...
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combinat...
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; ...
Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright
Investing.com - H.C. Wainwright lowered its price target on Nuvectis Pharma (NASDAQ:NVCT) to $10.00 from $15.00 on Monday, while maintaining a Buy rating on the stock. The company’s shares, curren...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
